Rock Creek Pharmaceuticals Inc. (fka RCPIQ)

[leifsmith]

Response to claim that there is no scientific support for STSI's claims.

Peer Reviewed Articles Exploring Star Scientific’s Anatabine* Compound
from http://www.starscientific.com/research-and-development/publications/

Title: Amelioration of Experimental Autoimmune Encephalomyelitis by Anatabine
Publication: PLOS ONE
This study, conducted by researchers at the Roskamp Institute, evaluated the effects of anatabine on the development of a standard mouse model of multiple sclerosis (MS) known as experimental autoimmune encephalomyelitis (EAE). Results showed that orally administered anatabine significantly reduced neurological disability and improved motor coordination of EAE mice; suppressed the production of several pro-inflammatory molecules (cytokines) in the blood and in the spleen of the mice; suppressed STAT3 and NF-kB activation in the spleen and the brain; and reduced the infiltration of inflammatory cells in the brain, and significantly prevented demyelination in the spinal cord of the EAE mice.
LINK: http://dx.plos.org/10.1371/journal.pone.0055392

Title: Anti-inflammatory Activity of Anatabine via Inhibition of STAT3 Phosphorylation
Publication: European Journal of Pharmacology
In a series of studies, researchers at the Roskamp Institute demonstrated that anatabine can suppress brain inflammation in animal models of Alzheimer’s disease, inflammation in the blood in mice, and inflammation induced in human blood once removed from the body. This peer-reviewed data supporting the view that anatabine has widespread anti-inflammatory properties was published in a paper, titled, “Anti-inflammatory Activity of Anatabine via Inhibition of STAT3 Phosphorylation”.
LINK: http://dx.doi.org/10.1016/j.ejphar.2012.11.017

Title: Anatabine Ameliorates Experimental Autoimmune Thyroiditis
Publication: Endocrinology
A pre-clinical investigator-initiated and independently funded study from Johns Hopkins University researchers examined the effect of anatabine supplementation in a mouse model of autoimmune thyroiditis. The results were published in September 2012 in an article entitled, “Anatabine Ameliorates Experimental Autoimmune Thyroiditis” in the Endocrine Society’s journal, Endocrinology. (Endocrinology. 2012 Sep; 153(9):4580-7.)
LINK: http://dx.doi.org/10.1210/en.2012-1452

Title: Anatabine Lowers Alzheimer’s Aß Production in vitro and in vivo
Publication: European Journal of Pharmacology
This peer-reviewed article explores the in vitro and in vivo activity of anatabine in Alzheimer’s disease. It states that anatabine lowers Alzheimer’s A-beta production in vitro and in vivo. The article is authored by scientists at the Roskamp Institute and is electronically published in the European Journal of Pharmacology (2011 Sept 19).
LINK: http://dx.doi.org/10.1016/j.ejphar.2011.09.019

*The anatabine used in the studies above is made under Star Scientific’s patented process and is the main ingredient in its Anatabloc® dietary supplement.